INTELLIA THERAPEUTICS, INC. financials

NTLA CIK 0001652130

Source: EDGAR filings · Built 2026-06-02T03:41:22Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -395.87M -354.66M -408.07M -346.85M -237.79M -53.50M
EBITDA -431.22M -523.98M -506.31M -450.59M -260.96M -130.27M
Working Capital 423.83M 529.01M 883.12M 1.09B 643.47M 552.26M
Net Debt -62.13M 21.02M -111.40M -392.80M -49.38M -120.72M
Gross Margin 100.00% 100.00%
Operating Margin -651.67% -923.10% -1420.51% -879.04% -810.37% -235.51%
Net Margin -609.85% -896.77% -1326.51% -909.78% -810.49% -231.46%
Return on Equity (ROE) -61.47% -59.52% -45.82% -38.38% -25.75% -25.47%
Return on Assets (ROA) -49.01% -43.58% -36.99% -31.19% -20.70% -19.85%
Current Ratio 5.08× 5.77× 8.67× 9.61× 6.11× 9.60×
Debt-to-Equity 0.14× 0.24× 0.11× 0.11× 0.07× 0.07×
Cash Conversion Ratio 0.96× 0.67× 0.82× 0.70× 0.84× 0.37×
Accruals Ratio -0.02× -0.14× -0.07× -0.09× -0.03× -0.12×
SBC % of Revenue 118.54% 266.55% 369.54% 175.36% 142.22% 34.32%
CapEx Coverage -349.63× -60.38× -28.18× -24.58× -17.64× -13.92×
Free Cash Flow Per Share $-3.65 $-3.59 $-4.60 $-4.51 $-3.35 $-0.96

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/S 15.45× 20.56× 78.17× 58.31× 266.46× 62.13×
P/B 1.56× 1.36× 2.70× 2.46× 8.47× 6.84×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 67.67M 57.88M 36.27M 52.12M 33.05M 57.99M
Cost of Goods and Services Sold 0 0
Research and Development Expense 388.86M 466.31M 435.07M 419.98M 229.81M 150.41M
Operating Income (Loss) -440.99M -534.26M -515.29M -458.16M -267.85M -136.58M
Income Tax Expense (Benefit) 0
Net Income (Loss) Attributable to Parent -412.69M -519.02M -481.19M -474.19M -267.89M -134.23M
Earnings Per Share, Basic $-3.81 $-5.25 $-5.42 $-6.16 $-3.78 $-2.40
Weighted Average Number of Shares Outstanding, Basic 108.38M 98.85M 88.77M 76.97M 70.89M 55.99M
Earnings Per Share, Diluted $-3.81 $-5.25 $-5.42 $-6.16 $-3.78 $-2.40
Weighted Average Number of Shares Outstanding, Diluted 108.38M 98.85M 88.77M 76.97M 70.89M 55.99M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 155.46M 189.18M 226.75M 523.51M 123.41M 160.02M
Assets, Current 527.71M 639.86M 998.33M 1.22B 769.30M 616.52M
Assets 842.13M 1.19B 1.30B 1.52B 1.29B 676.32M
Liabilities, Current 103.88M 110.85M 115.21M 126.55M 125.83M 64.25M
Liabilities 170.73M 319.06M 250.81M 284.53M
Stockholders' Equity Attributable to Parent 671.39M 871.96M 1.05B 1.24B 1.04B 527.07M
Common Stock, Shares, Outstanding 116.32M 102.03M 93.00M 87.10M 74.49M 66.23M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -394.74M -348.88M -394.09M -333.29M -225.03M -49.91M
Payments to Acquire Property, Plant, and Equipment 1.13M 5.78M 13.98M 13.56M 12.76M 3.58M
Net Cash Provided by (Used in) Investing Activities 228.03M 125.57M -31.35M 160.31M -550.78M -214.49M
Net Cash Provided by (Used in) Financing Activities 131.49M 185.75M 130.32M 582.96M 736.69M 371.78M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (NTLA CIK 0001652130), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

SAIC

Science Applications International Corporation

BH

BIGLARI HOLDINGS INC.

IMMX

IMMIX BIOPHARMA, INC.